Volume 11, Issue 2 (March & April - Special Issue on COVID-19 2020)                   BCN 2020, 11(2): 133-146 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Farhoudian A, Baldacchino A, Clark N, Gerra G, Ekhtiari H, Dom G, et al et al . COVID-19 and Substance Use Disorders: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper. BCN. 2020; 11 (2) :133-146
URL: http://bcn.iums.ac.ir/article-1-1743-en.html
1- Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran.; Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
2- Division of Population and Behavioral Sciences, St Andrews University Medical School, University of St Andrews, UK.
3- North Richmond Community Health, Victoria, Melbourne, Australia.; Royal Melbourne Hospital, Victoria, Melbourne, Australia.
4- Drug Prevention and Health Branch, Division for Operations, United Nations Office on Drugs and Crime, Vienna, Austria.
5- Laureate Institute for Brain Research, Tulsa, Oklahoma, USA.
6- Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium.
7- Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran.
8- Aftab Mehrvarzi Substance Abuse Treatment Center, Tehran, Iran.
9- Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
10- North Richmond Community Health, Victoria, Melbourne, Australia.
11- Department of Psychiatry, University of British Columbia, Vancouver BC, Canada.
12- Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
13- Clinical Tuberculosis and Epidemiology Research Center, National Research Institute for Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
14- Institute for Innovation and Improvement, IWaitematā DHB, Centre for Addictions Research, University of Auckland, Auckland, New Zealand.
15- Department of Medicine and Surgery, Section of Psychiatry, University of Milan Bicocca, Milan, Italy.
16- Norwegian Centre for Addiction Research (SERAF); University of Oslo, Oslo, Norway.
17- General Secretariat of Prime Minister, Ministry of Health, Athens, Greece.
18- Department of Psychology, National University of Singapore (NUS), Singapore.
19- Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.; Integrated Substance Abuse Programs, University of California, Los Angeles, California, USA.
Abstract:  
Coronavirus disease 2019 (COVID-19) is escalating all over the world and has higher morbidities and mortalities in certain vulnerable populations.  People Who Use Drugs (PWUD) are a marginalized and stigmatized group with weaker immunity responses, vulnerability to stress, poor health conditions, high-risk behaviors, and lower access to health care services. These conditions put them at a higher risk of COVID-19 infection and its complications. In this paper, an international group of experts on addiction medicine, infectious diseases, and disaster psychiatry explore the possible raised concerns in this issue and provide recommendations to manage the comorbidity of COVID-19 and Substance Use Disorder (SUD). 
Full-Text [PDF 1117 kb]   |   |   Full-Text (HTML)   
Type of Study: Review | Subject: Clinical Neuroscience
Received: 2020/04/7 | Accepted: 2020/04/9 | Published: 2020/07/1

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2020 All Rights Reserved | Basic and Clinical Neuroscience

Designed & Developed by : Yektaweb